U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
1188 articles about Allergan, Inc.
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year
As the $63 billion acquisition of Allergan by Chicago-based AbbVie slowly churns through the Federal Trade Commission (FTC) process, the company continues to make the news. Here’s a look.
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living
Allergan launches interactive website, MyGlaucoma.com, to shed light on the burden of the disease, provide patient and caregiver perspectives and resources to help
Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in eye care, today announced the launch of three new over-the-counter (OTC) REFRESH® RELIEVA™ products: REFRESH® RELIEVA™, REFRESH® RELIEVA™ PF (preservative-free) multidose, and REFRESH® RELIEVA™ FOR CONTACTS.
App Will Empower Breast Implant Patients by Providing a Digital Wallet with Their Implant Record and Serve as a Two-Way Doctor-Patient Communications Tool
Breast Tissue Expanders Market 2019-2023 | Evolving Opportunities with AirXpanders Inc. and Allergan Plc | Technavio
Technavio has been monitoring the global breast tissue expanders market and the market is poised to grow by USD 189.74 million during 2019-2023, progressing at a CAGR of over 6% during the forecast period.
Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting
Presentations include a late-breaking Abicipar abstract and topline Phase 3 results of Bimatoprost SR
Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market to Surpass US$ 1.3 Billion by 2026
Key players in the market are involved in expanding indication of approved drugs.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
AbbVie and Allergan entered into a definitive transaction agreement pursuant to which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019.
Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration
Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA) for Abicipar pegol,
Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
Allergan plc announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation.
Panish Shea & Boyle LLP and Bentley & More LLP File Lawsuits Against Allergan Relating to Recalled Natrelle BIOCELL Textured Breast Implants
Panish Shea & Boyle LLP and Bentley & More LLP today filed personal injury lawsuits against Allergan related to its line of Natrelle BIOCELL Textured Breast Implants that were recalled worldwide.
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma
According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.
Allergan plc reported its second quarter 2019 financial results including GAAP net revenues of $4.09 billion, a 0.8 percent decrease from the prior year quarter.
Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.S. financial markets.
Actress encourages women to take active roles in their reproductive health, including researching birth control options
Parker Waichman LLP is Reviewing Allergan's BIOCELL textured breast implants and Allergan's BIOCELL Breast Tissue Expander Lymphoma Cases
Allergan issued a worldwide recall of its BIOCELL textured breast implants and BIOCELL tissue expanders following reports of women being diagnosed with cancer, with some cases resulting in death.